First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients: a Randomized, Multicentre, Open-label Phase III Study
Latest Information Update: 26 Sep 2025
At a glance
- Drugs Atezolizumab (Primary) ; Cemiplimab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OliGRAIL
Most Recent Events
- 26 Aug 2025 Planned initiation date changed (estimated date for first patient recruitment) from 1 Jun 2025 to 9 Sep 2025.
- 22 Jun 2025 Planned initiation date changed from 1 May 2025 to 1 Jun 2025.
- 13 May 2025 Planned primary completion date changed from 28 Feb 2025 to 1 Feb 2030.